Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation

Jeffery D MacPherson1, Timothy D Gillespie, Heather A Dunkerley

  • 1Department of Pharmacology and Toxicology, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.

Insights

Tolerance to glyceryl trinitrate (GTN) involves increased phosphodiesterase (PDE) activity in veins. This study shows PDE5 inhibition can restore GTN

Area of Science:

  • Pharmacology
  • Cardiovascular Physiology
  • Nitrate Tolerance

Background:

  • Glyceryl trinitrate (GTN) is an antianginal drug with a key venodilator effect.
  • Chronic GTN exposure can lead to tolerance, reducing its efficacy.
  • The mechanism of nitrate tolerance, particularly in the venous circulation, requires further investigation.

Purpose of the Study:

  • To investigate the role of phosphodiesterase (PDE) activity in the development of GTN tolerance.
  • To determine if increased PDE activity in the venous circulation contributes to altered hemodynamic responses to GTN.

Main Methods:

  • Induction of GTN tolerance in rats via continuous GTN exposure.
  • Tension recordings of isolated rat femoral artery and vein.
  • Assessment of GTN-induced relaxation using PDE5 inhibitors (MBCQ and zaprinast).
  • Measurement of cyclic guanosine monophosphate (cGMP) PDE activity in vascular tissues.
  • Evaluation of hemodynamic responses (CVP and MAP) to GTN in conscious, ganglionic-blocked rats.

Main Results:

  • GTN tolerance was more pronounced in the femoral vein compared to the artery.
  • The PDE5 inhibitor MBCQ shifted the GTN dose-response curve significantly, especially in tolerant veins.
  • cGMP PDE activity increased in tolerant femoral veins but not in arteries.
  • The PDE inhibitor zaprinast selectively reversed blunted central venous pressure responses to GTN in tolerant rats.

Conclusions:

  • Increased PDE5 activity in the venous circulation is a significant factor contributing to GTN tolerance.
  • Targeting PDE5 may be a therapeutic strategy to overcome nitrate tolerance.
  • These findings elucidate a key mechanism underlying the diminished antianginal efficacy of GTN during chronic use.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...